Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

PET/CT Imaging of Human TNFα Using [89Zr]Certolizumab Pegol in a Transgenic Preclinical Model of Rheumatoid Arthritis

  • 259 Accesses

  • 1 Citations

Abstract

Purpose

Tumor necrosis factor alpha (TNFα) drives inflammation and bone degradation in patients with rheumatoid arthritis (RA). Some RA patients experience a rapid clinical response to TNFα inhibitors such as certolizumab pegol (CZP) while other patients show limited to no response. Current methods for imaging RA have limited sensitivity and do not assist in the selection of patients most likely to respond to immune-mediated therapy. Herein, we developed a novel positron emission tomography (PET) radiotracer for immuno-PET imaging of TNFα in transgenic human TNFα-expressing mice.

Procedures

CZP was modified with p-isothiocyanatobenzyl-deferoxamine (DFO) and radiolabeled with Zr-89. The biological activity of [89Zr]DFO-CZP was evaluated by HPLC and binding assay using human recombinant TNFα (hTNFα). The feasibility of specific immuno-PET imaging of human TNFα was assessed in a transgenic mouse model of RA that expresses human TNFα. This model resembles the progression of RA in humans by maintaining lower levels of circulating hTNFα and exhibits chronic arthritis in the forepaw and hind paw joints. The dosimetry of [89Zr]DFO-CZP in humans was estimated using microPET/CT imaging in Sprague Dawley rats.

Results

[89Zr]DFO-CZP was isolated with radiolabeling yields of 85 ± 6 % (n = 5) and specific activities ranging from 74 to 185 MBq/mg (n = 5). Following size exclusion purification, the radiochemical purity of [89Zr]DFO-CZP was greater than 97 %. [89Zr]DFO-CZP retained high immunoreactivity with more than 95 % of the radioactivity shifted into higher molecular weight complexes. Images showed increasing uptake of the tracer in forepaw and hind paw joints with disease progression. No uptake was observed in the model previously administered with an excess amount of unmodified CZP and in normal control mice, demonstrating in vivo specific uptake of [89Zr]DFO-CZP.

Conclusion

The feasibility of immuno-PET imaging of human TNFα with [89Zr]DFO-CZP has been demonstrated in a preclinical model of RA.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. 1.

    Alfonso-Cristancho R, Armstrong N, Arjunji R, Riemsma R, Worthy G, Ganguly R, Kleijnen J (2017) Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clin Rheumatol 36:25–34

  2. 2.

    Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11:276–289

  3. 3.

    Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37

  4. 4.

    Kaeley GS, MacCarter DK, Goyal JR et al (2018) Similar improvements in patient-reported outcomes among rheumatoid arthritis patients treated with two different doses of methotrexate in combination with adalimumab: results from the MUSICA trial. Rheumatol Ther 5:123–134

  5. 5.

    Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364–371

  6. 6.

    van Schie KA, Heer PO-D, Dijk L et al (2016) Therapeutic TNF inhibitors can differentially stabilize trimeric TNF by inhibiting monomer exchange. Nat Publ Group 6:1–10

  7. 7.

    Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196

  8. 8.

    Zhou Q, Zhou Y, Chen H, Wang Z, Tang Z, Liu J (2014) The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials. Int J Clin Exp Med 7:3870–3880

  9. 9.

    Curtis JR, Luijtens K, Kavanaugh A (2012) Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res 64:658–667

  10. 10.

    Haavardsholm EA, Østergaard M, Hammer HB et al (2009) Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Ann Rheum Dis 68:1572–1579

  11. 11.

    Goel N, Stephens S (2010) Certolizumab pegol. Mabs 2:137–147

  12. 12.

    Lambert B, Carron P, D’Asseler Y et al (2016) 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study. EJNMMI Res 6:1–9

  13. 13.

    Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A (2010) Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 37:386–398

  14. 14.

    Zeman MN, Scott PJ (2012) Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2:174–220

  15. 15.

    Bugatti S, Manzo A, Montecucco C, Caporali R (2018) The clinical value of autoantibodies in rheumatoid arthritis. Front Med (Lausanne) 5:339

  16. 16.

    Cao Q, Cai W, Li Z-B, Chen K, He L, Li HC, Hui M, Chen X (2007) PET imaging of acute and chronic inflammation in living mice. Eur J Nucl Med Mol Imaging 34:1832–1842

  17. 17.

    Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51:1293–1300

  18. 18.

    Beckford Vera DR, Smith CC, Bixby LM, Glatt DM, Dunn SS, Saito R, Kim WY, Serody JS, Vincent BG, Parrott MC (2018) Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS One 13:e0193832

  19. 19.

    Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GAMS, Verheul HM, Menke CW, Huisman MC (2015) PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab. J Nucl Med 56:249–254

  20. 20.

    Börjesson PKE, Jauw YWS, de Bree R et al (2009) Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 50:1828–1836

  21. 21.

    Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O’Donoghue JA (2018) First-in-human human epidermal growth factor receptor 2-targeted imaging using 89Zr-pertuzumab PET/CT: dosimetry and clinical application in patients with breast Cancer. J Nucl Med 59:900–906

  22. 22.

    Chang AJ, DeSilva R, Jain S, Lears K, Rogers B, Lapi S (2012) 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals 5:79–93

  23. 23.

    Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89

  24. 24.

    Wu AM, Yazaki PJ, Tsai SW, Nguyen K, Anderson AL, McCarthy DW, Welch MJ, Shively JE, Williams LE, Raubitschek AA, Wong JYC, Toyokuni T, Phelps ME, Gambhir SS (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 97:8495–8500

  25. 25.

    Palframan R, Airey M, Moore A, Vugler A, Nesbitt A (2009) Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 348:36–41

  26. 26.

    Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–1458

  27. 27.

    Hayward MD, Jones BK, Saparov A, Hain HS, Trillat AC, Bunzel MM, Corona A, Li-Wang B, Strenkowski B, Giordano C, Shen H, Arcamone E, Weidlick J, Vilensky M, Tugusheva M, Felkner RH, Campbell W, Rao Y, Grass DS, Buiakova O (2007) An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol 7:13

Download references

Acknowledgments

The authors would like to thank Dr. Thomas R. Hayes for assistance with the figures of this manuscript.

Funding

This work was funded by UCSF RAP awarded to Dr. Benjamin Franc and Dr. Xiaojuan Li.

Author information

Correspondence to Denis R. Beckford-Vera.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 826 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Beckford-Vera, D.R., Gonzalez-Junca, A., Janneck, J.S. et al. PET/CT Imaging of Human TNFα Using [89Zr]Certolizumab Pegol in a Transgenic Preclinical Model of Rheumatoid Arthritis. Mol Imaging Biol 22, 105–114 (2020). https://doi.org/10.1007/s11307-019-01363-0

Download citation

Key words

  • Molecular imaging
  • PET/CT
  • TNFα
  • Certolizumab pegol
  • Rheumatoid arthritis